CGT

5개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
CGTStandard DatabasestaleSPP Pharmaclon Ltd.Phase 2

Recombinant Interferon Alfa (Recombinant Interferon Alfa)

Colorectal Cancer; Kidney Cancer · Bladder Cancer

#BladderCancer#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte (PG13-A(F/K-F-SGSG-T2a-B (opt, (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte)

Renal Cancer; Kidney Cancer · Renal Cancer

#RenalCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

2G-1 TCR Retroviral Vector-Transduced lyn (2G-1 TCR Retroviral Vector-Transduced lyn)

Renal Cancer; Kidney Cancer · Renal Cancer

#RenalCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleAMERICAN ORGAN TRANSPLANT AND C…Phase 2

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney)

End-Stage Renal Disease; End Stage Renal Disease on Dialysis · End-Stage Renal Disease

#End-StageRenalDisease#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19/BCMA U CAR T (anti-CD19/BCMA U CAR T)

Relapsed/Refractory Immune Nephropathy; Relapsed/Refractory Immune-mediated Kidney Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting